Phase 2 N=81 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Engraftment — 15; 15 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Prostate Cancer
Primary: Progression-Free Survival (PFS) — 2.3; 2.4 months — p=0.2201
Phase 2 N=102 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Breast Cancer
Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR
Phase 2 N=72 Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Objective Response Assessed by Independent Review Committee — 31; 58 percentage of participants
Phase 2 N=179 Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia
Vitamin D Deficiency · Pre-Eclampsia
Primary: Number of Participants With Pre-eclampsia in Both Arms — 6; 1 Participants — p=<0.05
Phase 2 N=374 A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Primary Progressive Multiple Sclerosis
Primary: Percent Brain Volume Change (PBVC) From Baseline to Week 48 Using a Repeated Measures ANCOVA Model — -0.454; -0.438 percentage change from baseline — p=0.903
Phase 2 N=30 Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Primary: Change in Dark Adaptation, Rod Intercept — 0.3; -0.3 minutes — p=.70
Phase 2 N=84 Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Chronic Phase Chronic Myeloid Leukemia
Primary: Major Molecular Response (MMR) Rate — 47.6 Percentage of Participants
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
Phase 2 N=334 A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -50.7; -40.6; -13.3; 4.6 Percentage Change
Phase 2 N=145 Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12…
Phase 2 N=12 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
Hypogonadism
Primary: Mean Serum Testosterone Cavg — 293; 246; 281; 385 ng/dL